Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients.

ABSTRACT:

Abstract

Up to a third of patients with hemato-oncologic conditions who have received multiply transfusions develop immune-mediated platelet transfusion refractoriness. Yet factors that influence posttransfusion platelet corrected count increments (CCI) in patients with HLA-alloimmune platelet transfusion refractoriness remain less well elucidated. Recent advances in HLA antibody characterization using fluorescent bead-based platforms enable the study of donor-specific antibody (DSA) avidity (as measured by mean fluorescence intensity [MFI]) and its impact on HLA-alloimmune platelet transfusion refractoriness. In this large retrospective study of 2012 platelet transfusions among 73 HLA-alloimmunized patients, we evaluated the impact of cumulative HLA DSA-MFI alongside other donor,

SUBMITTER: Boothby AB 

PROVIDER: S-EPMC11402140 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature